Eastern Cooperative Oncology Group

描述（由申请人提供）：马约诊所已成为东部肿瘤协作组（ECOG）的成员37年。提交此申请是为了通过U10机制申请资金，以继续作为ECOG的主要机构成员。马约诊所的教师和附属机构参与了关键的科学作用，包括临床和转化研究。马约诊所是一个国家癌症研究所指定的综合癌症中心，自1973年以来一直得到资助。从历史上看，马约诊所癌症中心（MCCC）的主要优势在于高质量的临床研究、实践定义的临床试验、多学科转化研究和生物统计学。在2004年1月1日至2008年12月3日期间，4，114例患者被主要机构、CGOP和次要CCOP纳入ECOG研究。 与马约或马约附属作者一起发表了98篇全文手稿，并提交了89篇摘要，而上一个资助周期为55篇论文和58篇摘要。主要成就如下。马约的主要研究者是两项试验的作者，这些试验使用的是FDA批准的适应症新药（利妥昔单抗治疗弥漫性大B细胞淋巴瘤（E4494 Dr. TM Habermann）和沙利度胺治疗多发性骨髓瘤（E1 A04 Dr. SV Rajkumar））。高剂量地塞米松的血栓形成风险改变了骨髓瘤的实践（E4 A03 SV Rajkumar博士）。在白血病方面，细胞遗传学委员会主席GW Dewald博士报告说，复杂的核型导致急性淋巴细胞白血病预后不良，治疗失败的风险增加。在多发性骨髓瘤中，R. Fonseca及其同事。具体目标是1）。作为主要机构，以及通过CGOP计划和二级CCOP计划，促进ECOG研究的累积，2.）为ECOG提供与降低恶性肿瘤相关发病率和死亡率的ECOG使命一致的临床科学领导和资源，3.）提供基础和转化科学领导和资源，以促进恶性疾病生物学知识的发展，特别强调马约诊所独特的疾病导向专业知识和/或计划，以及4.）在西非经共体发挥行政作用，支持该小组的使命和目标。 相关性：参与和贡献这一机制导致新的治疗方法，改变了弥漫性大B细胞淋巴瘤和多发性骨髓瘤的自然史，提高了患者的生存率。生物学观察是预测结果，并在患者中采用新的治疗方法，其结果与其呈现的生物学预测的结果相同。

DESCRIPTION (provided by applicant): The Mayo Clinic has been a member of the Eastern Cooperative Oncology Group (ECOG) for 37 years. This application is submitted to request funding via the U10 mechanism to continue as a main institution member of the ECOG. Mayo Clinic faculty and affiliated institutions have participated in key scientific roles including clinical and translational studies. The Mayo Clinic is an NCI-designated Comprehensive Cancer Center that has been continuously funded since 1973. Historically, the major strengths of the Mayo Clinic Cancer Center (MCCC) have been in high quality clinical research, practice-defining clinical trials, multidisciplinary translational studies, and biostatistics. Between 1/1/04 and 12/3/08, 4,114 patients were accrued to ECOG studies by the main institution, CGOPs, and secondary CCOPs. 98 full-length manuscripts were published with Mayo or Mayo affiliate authors and 89 abstracts were presented versus 55 papers and 58 abstracts in the previous grant cycle. Major accomplishments include the following. Mayo principal investigator authorship occurred on two trials with new agents that lead to FDA-approved indications (rituximab in diffuse large B-cell lymphoma (E4494 Dr. TM Habermann) and thalidomide in multiple myeloma (E1A04 Dr. SV Rajkumar). The thrombotic risks of high-dose dexamethasone changed the practice in myeloma (E4A03 Dr SV Rajkumar). In leukemia, Dr. GW Dewald as Chair of the Cytogenetics Committee, reported that a complex karyotype confers a poor prognosis with increased risk of treatment failure in acute lymphocytic leukemia. In multiple myeloma, new biologic insights were reported in the clinical implications of t(11,14) and tumor suppressor pl6 methylation by Dr. R. Fonseca and colleagues. The specific aims are 1.) to contribute to accrual to ECOG studies as a main institution, and through CGOP programs and secondary CCOP programs, 2.) to provide clinical scientific leadership and resources to the ECOG consistent with the ECOG mission of reducing malignancy-related morbidity and mortality, 3.) to provide basic and translational scientific leadership and resources for the advancement of knowledge of the biology of malignant diseases with particular emphasis on disease-oriented expertise and/or programs unique to the Mayo Clinic, and 4.) to provide an administrative role in ECOG to support the Group's mission and goals. RELEVANCE: Participation and contributions in this mechanism have lead to new therapeutic approaches that have changed the natural history of diffuse large B-cell lymphoma and multiple myeloma improving patient survival. Biologic observations are predicting outcomes and moving to new therapeutic approaches in patients with outcomes as predicted by their presenting biology.